Allianz Asset Management
KYTX icon

Allianz Asset Management’s Kyverna Therapeutics KYTX Stock Holding History

Allianz Asset Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98K Buy
+11,000
New +$97.7K ﹤0.01% 2112

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Allianz Asset Management's KYTX Position: Q2 2026 in Review

Allianz Asset Management opened a new position in Kyverna Therapeutics (KYTX) in Q2 2026: 11,000 shares worth $98K. The stake represents ﹤0.01% of the portfolio and ranks #2112 among its holdings.

121 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Allianz Asset Management held 11,000 shares of Kyverna Therapeutics worth $98K as of Q2 2026.
  • Kyverna Therapeutics was a new Allianz Asset Management position in Q2 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #2112 holding.
  • 121 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.